tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
van den Berg JW et al. New immunosuppressive drugs and lung transplantation: last or least? 1999 Thorax pmid:10335012
Shirbacheh MV et al. Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. 1999 J. Pharmacol. Exp. Ther. pmid:10336506
Gold BG et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. 1999 J. Pharmacol. Exp. Ther. pmid:10336507
Steg RE et al. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. 1999 Bone Marrow Transplant. pmid:10338054
Ferrand-Drake M et al. Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. 1999 Neuroscience pmid:10338300
Conboy IM et al. Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10339586
Ma D and Carlow CK Molecular characterization of FKBP13 from filarial parasites. 1999 Mol. Biochem. Parasitol. pmid:10340490
Ruddy SB et al. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. 1999 Int J Pharm pmid:10341307
Uchio E et al. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. 1999 Mar-Apr Clin. Exp. Rheumatol. pmid:10342043
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Khanna A et al. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. 1998 Transpl. Immunol. pmid:10342736
Dresske B et al. WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. 1998 Transpl. Immunol. pmid:10342738
Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. 1998 Prescrire Int pmid:10342948
Boehringer M et al. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. 1999 Nephrol. Dial. Transplant. pmid:10344407
Siemann G et al. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. 1999 Mol. Pharmacol. pmid:10347253
Oddis CV et al. Tacrolimus in refractory polymyositis with interstitial lung disease. 1999 Lancet pmid:10347992
Araki T et al. Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. 1999 Metab Brain Dis pmid:10348311
Möller A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. 1999 Drug Metab. Dispos. pmid:10348790
Murata M et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. 1999 Br. J. Haematol. pmid:10354150
Zarifian A et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. 1999 Kidney Int. pmid:10354295
Yang J et al. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. 1999 Pathol. Int. pmid:10355966
Toung TJ et al. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. 1999 Stroke pmid:10356112
Muramatsu K et al. Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. 1999 J Hand Surg Am pmid:10357540
Cheng HH et al. Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. 1999 J. Biol. Chem. pmid:10358074
Cao S et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. 1999 Pediatr Transplant pmid:10359027
Doolabh VB and Mackinnon SE FK506 accelerates functional recovery following nerve grafting in a rat model. 1999 Plast. Reconstr. Surg. pmid:10359255
Johnson KL and Lawen A Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. 1999 Immunol. Cell Biol. pmid:10361256
Gummert JF et al. Newer immunosuppressive drugs: a review. 1999 J. Am. Soc. Nephrol. pmid:10361877
Kanoh S et al. Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. 1999 Am. J. Physiol. pmid:10362712
Jiang H et al. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. 1999 Transpl. Int. pmid:10363590
Venz S et al. Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. 1999 Transpl. Int. pmid:10363595
Onsager DR et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. 1999 J. Heart Lung Transplant. pmid:10363689
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Przepiorka D et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. 1999 Biol. Blood Marrow Transplant. pmid:10371361
Matzinger P Graft tolerance: a duel of two signals. 1999 Nat. Med. pmid:10371494
Kirk AD et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 1999 Nat. Med. pmid:10371508
Lieberman DN and Mody I Properties of single NMDA receptor channels in human dentate gyrus granule cells. 1999 J. Physiol. (Lond.) pmid:10373689
Cox KL et al. Paediatric liver transplantation: indications, timing and medical complications. 1999 J. Gastroenterol. Hepatol. pmid:10382641
Higgins RM et al. Conversion between cyclosporin and tacrolimus--30-fold dose prediction. 1999 Nephrol. Dial. Transplant. pmid:10383044
Henry ML Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. 1999 Clin Transplant pmid:10383101
Koski GK et al. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. 1999 J. Immunol. pmid:10384103
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Squadrito F et al. Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. 1999 Br. J. Pharmacol. pmid:10385251
Gerhardt U et al. Blood pressure control in kidney transplant recipients: influence of immunosuppression. 1999 J Auton Pharmacol pmid:10385269
Liang H et al. Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. 1999 J. Biol. Chem. pmid:10391929
Hasselder AS The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. 1998 Apr-Jun EDTNA ERCA J pmid:10392057
Horowitz MM et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. 1999 Biol. Blood Marrow Transplant. pmid:10392964
Kochi S et al. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. 1999 Eur. J. Pharmacol. pmid:10395024
Magee CC et al. Immunosuppressive agents in organ transplantation. 1999 Hosp Med pmid:10396414
Gold BG et al. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. 1999 Neurosci. Lett. pmid:10400242